Regular insulin

Limits on what this shows

• Null/negative findings: Not independently retrieved this session; not actively ruled out.
• At-risk subgroups: Patients receiving IV or high-dose insulin (DKA treatment, deliberate hyperkalemia treatment, insulin-overdose management); patients with pre-existing hypokalemia risk from diuretics, poor intake, or other renal potassium loss.
• Counter-evidence: None independently retrieved this session; this is disclosed as an open item rather than treated as absence of counter-evidence.

Regulatory status

The Humulin R label states directly: "All insulins, including HUMULIN R, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia... Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk."

Population evidence

Tier A regulatory-label statement, drug named explicitly. This action is also the basis for the standard clinical use of insulin plus glucose to treat hyperkalemia. A second, independently opened peer-reviewed primary study quantifying magnitude/time-course in an insulin-treated cohort was sought but could not be retrieved this session (tooling limitation; see access note).

Mechanism

Insulin receptor activation stimulates Na + /K + -ATPase in skeletal muscle and liver, driving potassium into cells independently of its glucose-lowering action; named directly in the label's interaction language.

Counter-evidence held on record

This is a redistribution effect, not a dietary deficiency. Potassium should be monitored and replaced under medical supervision during acute insulin therapy; it is not an indication for routine potassium supplementation with maintenance insulin use, and inappropriate supplementation in this context risks hyperkalemia once the shift reverses.

Limits on what this shows

• Null/negative findings: The Wilson et al. 1982 trial specifically tested whether phosphate replacement during DKA improved outcomes; per the available search summary this line of research has generally not shown routine phosphate supplementation to reliably improve clinical outcomes despite the biochemical drop, an important counter-point against treating the low level as automatically requiring correction. Full study text was not reopened this session to confirm exact conclusions.
• At-risk subgroups: Patients being treated for DKA, particularly pediatric patients per the 2024 observational study; malnourished or refeeding patients receiving concurrent insulin and glucose.
• Counter-evidence: See null findings above (uncertain benefit of routine phosphate replacement in DKA).

Regulatory status

Not addressed in the Humulin R label's interaction section (the label names potassium explicitly but not phosphate); this signal comes from the clinical literature.

Population evidence

PubMed search identified insulin/DKA-specific primary literature: Riley, Schade, Eaton (1979, PMID 105228), a direct comparison of insulin infusion rates and plasma phosphate in diabetic patients; Wilson et al. (1982, PMID 6802095), a randomized trial of phosphate therapy during DKA treatment, n=44; Sanluis Fenelli et al. (2024, PMID 38801366), an observational study of hypophosphatemia in children receiving subcutaneous insulin for DKA; case reports of symptomatic hypophosphatemia during DKA insulin treatment (Choi et al. 2018, PMID 29969883; Yoshida and Takemoto 2021, PMID 32654423). These were identified via PubMed search-listing summaries; full-text/abstract pages were not independently reopened this session due to tooling rate-limiting, so exact effect sizes are not reported here.

Mechanism

Insulin increases cellular glucose uptake and glycolytic flux, which draws phosphate into cells alongside potassium (phosphate is required for phosphorylated glycolytic intermediates and ATP synthesis); the same transcellular-shift physiology underlying the potassium effect.

Counter-evidence held on record

This is a treatment-phase electrolyte shift managed by the treating clinical team, not a basis for consumer phosphate supplementation. Do not present this as a reason to take phosphate supplements outside of monitored acute care.

Limits on what this shows

• Null/negative findings: Not independently retrieved this session.
• At-risk subgroups: Patients receiving high-dose IV insulin; refeeding-syndrome-risk patients receiving concurrent glucose and insulin.
• Counter-evidence: Not independently retrieved this session; the smaller, more review-heavy evidence base is itself the reason for the cautious yellow grade rather than orange.

Regulatory status

Not mentioned in the Humulin R label.

Population evidence

Xu and Maalouf (2017, PMID 27546733), "Effect of acute hyperinsulinemia on magnesium homeostasis in humans," a human study with direct insulin administration; Amano et al. (2000, PMID 10864878), a mechanistic study of insulin modulation of intracellular free magnesium in heart tissue (species/tissue not independently confirmed this session); Paolisso and Barbagallo (1997, PMID 9056694) and Barbagallo et al. (2003, PMID 12537988), narrative reviews on magnesium and insulin action focused mainly on endogenous insulin resistance rather than exogenous insulin-drug dosing; Lambers et al. (2015, PMID 25827151), a general refeeding-syndrome review naming insulin-driven potassium, phosphate, and magnesium shifts together. None of these were reopened at full text this session (tooling limitation).

Mechanism

Proposed to share the transcellular-shift physiology described for potassium and phosphate, though the transporter-level mechanism for magnesium is less well characterized in what could be reviewed this session.

Counter-evidence held on record

Evidence is mechanistic and preliminary. This is not a basis for magnesium supplementation and should not be presented to consumers as an established deficiency risk.